181 related articles for article (PubMed ID: 25379611)
1. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
[TBL] [Abstract][Full Text] [Related]
3. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
[TBL] [Abstract][Full Text] [Related]
4. Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
Shen F; Long D; Yu T; Chen X; Liao Y; Wu Y; Lin X
Oncol Rep; 2017 Apr; 37(4):2481-2489. PubMed ID: 28259950
[TBL] [Abstract][Full Text] [Related]
5. The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.
Chen X; Liao Y; Long D; Yu T; Shen F; Lin X
Int J Mol Med; 2017 Jul; 40(1):235-242. PubMed ID: 28534969
[TBL] [Abstract][Full Text] [Related]
6. RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
Long D; Yu T; Chen X; Liao Y; Lin X
Cell Biol Toxicol; 2018 Feb; 34(1):7-21. PubMed ID: 28589243
[TBL] [Abstract][Full Text] [Related]
7. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
Chen S; Zhao Y; Shen F; Long D; Yu T; Lin X
Oncol Rep; 2019 Mar; 41(3):2051-2059. PubMed ID: 30628717
[TBL] [Abstract][Full Text] [Related]
8. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y
Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
[TBL] [Abstract][Full Text] [Related]
9. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
Feng W; Xiaoyan X; Xuan Y; Xiangke L; Zichang Y; Ran Z; Liuxing W; Qingxia F
Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118
[TBL] [Abstract][Full Text] [Related]
10. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
Mistry SJ; Bank A; Atweh GF
Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914
[TBL] [Abstract][Full Text] [Related]
12. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.
Nishio K; Nakamura T; Koh Y; Kanzawa F; Tamura T; Saijo N
Cancer; 2001 Apr; 91(8):1494-9. PubMed ID: 11301397
[TBL] [Abstract][Full Text] [Related]
13. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.
Singer S; Ehemann V; Brauckhoff A; Keith M; Vreden S; Schirmacher P; Breuhahn K
Hepatology; 2007 Sep; 46(3):759-68. PubMed ID: 17663418
[TBL] [Abstract][Full Text] [Related]
14. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
[TBL] [Abstract][Full Text] [Related]
15. In vitro neutralization of autocrine IL‑10 affects Op18/stathmin signaling in non‑small cell lung cancer cells.
Zhao Y; Chen S; Shen F; Long D; Yu T; Wu M; Lin X
Oncol Rep; 2019 Jan; 41(1):501-511. PubMed ID: 30320402
[TBL] [Abstract][Full Text] [Related]
16. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
18. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics.
Gonçalves A; Braguer D; Kamath K; Martello L; Briand C; Horwitz S; Wilson L; Jordan MA
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11737-42. PubMed ID: 11562465
[TBL] [Abstract][Full Text] [Related]
19. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
20. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
Balachandran R; Welsh MJ; Day BW
Oncogene; 2003 Dec; 22(55):8924-30. PubMed ID: 14654788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
